Stockreport

Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

Artiva Biotherapeutics, Inc.  (ARTV) 
PDF Initial clinical response data for AlloNK® in refractory rheumatoid arthritis (RA) expected in first half of 2026 U.S. Food and Drug Administration (FDA) interaction to [Read more]